Rucaparib Tablets — PARP Inhibitor for Advanced Ovarian and Prostate Cancer
Bdparib® (Rucaparib) — PARP Inhibitor for BRCA-Mutated Ovarian and Prostate Cancer
A Sourcing Guide for Hospitals and Oncology Centres
Bdparib® (Rucaparib) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor indicated, according to its approved prescribing information, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who are in a complete or partial response to platinum-based chemotherapy, and for the treatment of BRCA mutation-associated metastatic castration-resistant prostate cancer in adults previously treated with androgen receptor-directed therapy. As with all biomarker-directed oncology therapies, the decision to prescribe Bdparib, including BRCA mutation testing and patient selection, rests entirely with the treating oncologist, in accordance with the approved label. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharma distribution company, A.K. Pharma supplies genuine Bdparib (Rucaparib) in both 200mg and 300mg tablet strengths to hospitals, oncology centres, and pharmacies across India, manufactured by BDR Pharmaceuticals. Among pharmaceutical distribution companies operating in Delhi, A.K. Pharma maintains one of the most comprehensive specialty oncology portfolios — hospitals managing broader oncology caseloads can source companion medicines through A.K. Pharma’s full product range.
Bdparib contains Rucaparib, a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes — specifically PARP-1, PARP-2, and PARP-3 — which are involved in repairing single-strand DNA breaks in cells.
PARP Inhibition and Synthetic Lethality:
According to published oncology literature, PARP enzymes play a critical role in repairing single-strand DNA breaks. In cells with functioning BRCA1/2 genes, double-strand DNA breaks are repaired through homologous recombination. However, in cancer cells harbouring BRCA1 or BRCA2 mutations, homologous recombination is defective, making those cells dependent on PARP-mediated repair to survive. By inhibiting PARP, Rucaparib traps PARP on damaged DNA and prevents its repair activity, causing the accumulation of double-strand DNA breaks that BRCA-mutated cancer cells cannot fix — a concept known as synthetic lethality in published clinical oncology literature.
Rucaparib’s Mechanism: By binding to and inhibiting PARP-1, PARP-2, and PARP-3, Bdparib blocks PARP-mediated DNA repair activity, according to the manufacturer’s prescribing information. This mechanism is particularly effective in tumours with deficient homologous recombination repair — most commonly due to BRCA1/2 mutations — making BRCA testing a prerequisite for certain indications, similar to other PARP inhibitors available from A.K. Pharma including Bracanat (Olaparib) and Lynpraza (Olaparib).
Full prescribing information is available at the FDA label for Rucaparib, with additional background on PARP inhibitor therapy available via the National Cancer Institute and the American Society of Clinical Oncology (ASCO).
ARIEL3 Trial (Rucaparib Maintenance in Recurrent Ovarian Cancer)
Published in the Lancet (2017), the pivotal ARIEL3 trial evaluated Rucaparib as maintenance therapy in patients with recurrent ovarian cancer who had achieved a complete or partial response to platinum-based chemotherapy. Key findings demonstrated a significant improvement in progression-free survival across all pre-specified patient subgroups — those with BRCA mutations, homologous recombination deficiency, and the intention-to-treat population — supporting its approval as maintenance therapy in this setting.
TRITON2 Trial (Rucaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer)
Published in the Journal of Clinical Oncology (2020), the TRITON2 trial evaluated Rucaparib in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer who had progressed on androgen receptor-directed therapy and taxane-based chemotherapy. Key findings demonstrated a meaningful radiographic response rate in BRCA1/2-mutated patients, supporting its approval in this prostate cancer population.
For broader clinical guidance on PARP inhibitor therapy, the Society of Gynecologic Oncology (SGO) and NCCN Guidelines publish ongoing treatment recommendations.
Bdparib is supplied in two strengths:
| Presentation | Strength | Standard Daily Dose |
|---|---|---|
| Bdparib Tablets | 200mg per tablet | 600mg twice daily (three 200mg tablets per dose) |
| Bdparib Tablets | 300mg per tablet | 600mg twice daily (two 300mg tablets per dose) |
Both strengths deliver the same 600mg twice daily dose per the approved prescribing information — the 300mg tablets require fewer tablets per dose, while the 200mg tablets provide more flexibility for dose reductions. Dose reduction to 500mg or 400mg twice daily is permitted for toxicity management per the approved label.
Maintenance Treatment of Recurrent Ovarian Cancer:
BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer:
For detailed indication information refer to MedlinePlus Rucaparib and the Ovarian Cancer Research Alliance.
Cost-Effective Access to an Established PARP Inhibitor
As India’s first affordable generic of Rucaparib, manufactured by BDR Pharmaceuticals, Bdparib provides hospitals and patients access to this established PARP inhibitor at significantly more accessible pricing than the originator Rubraca. For hospitals working with pharmaceutical distributors who understand the Indian oncology generic landscape, Bdparib represents a meaningful cost reduction without compromising on clinical mechanism.
Two Strengths for Dosing Flexibility
Availability in both 200mg and 300mg strengths allows oncologists to select the most appropriate tablet strength for each patient’s dose and any required dose reductions, without tablet splitting.
Dual Indication Across Gynaecologic and Genitourinary Oncology
Bdparib’s approvals across both ovarian cancer maintenance and BRCA-mutated prostate cancer reflect the broad relevance of PARP inhibition in cancers with deficient homologous recombination repair.
Established Clinical Evidence Base
ARIEL3 and TRITON2 provide a substantial clinical evidence foundation across both approved indications, published in major peer-reviewed journals.
Dosing of Bdparib is determined by the prescribing oncologist according to the approved label. General administration information from the manufacturer’s prescribing information includes:
Monitoring (per manufacturer prescribing information):
Full dosing guidelines are available in the manufacturer’s official prescribing information and should always be followed exactly as directed by the treating oncologist.
Bdparib is prescribed by oncologists for:
Bdparib is prescribed by oncologists specialising in gynaecologic and genitourinary malignancies. As a licensed pharma distribution company in Delhi, A.K. Pharma supplies Bdparib to hospitals and oncology centres across India.
Common side effects reported in clinical trials include nausea, fatigue, anaemia, elevated liver enzymes, vomiting, decreased appetite, dysgeusia, constipation, and diarrhoea.
Serious side effects include:
Haematological Toxicity: Anaemia, thrombocytopenia, and neutropenia have been reported as common adverse events; regular complete blood count monitoring is required per the approved prescribing information.
Myelodysplastic Syndrome/Acute Myeloid Leukaemia (MDS/AML): A rare but serious complication associated with the PARP inhibitor class; monitoring for signs and symptoms is recommended throughout treatment.
Photosensitivity: Increased sensitivity to sunlight has been reported; patients should be counselled to use sun protection during treatment.
Embryo-Fetal Toxicity: Rucaparib can cause fetal harm; effective contraception is required during and for a defined period after treatment, per the approved label.
Full side effect information is available at FDA Rucaparib Safety Information.
As one of Delhi’s most trusted pharmaceutical distribution companies, A.K. Pharma stores all oncology medicines including Bdparib under manufacturer-recommended conditions ensuring product integrity for every supply.
Bdparib (Rucaparib) is manufactured by BDR Pharmaceuticals, one of India’s leading oncology generic pharmaceutical companies, as the first affordable Indian generic of Rucaparib — the same active ingredient as the originator Rubraca (Clovis Oncology/Pfizer). Unlike wholesale pharmaceutical distributors who source through multiple intermediary channels, A.K. Pharma sources only genuine Bdparib directly from authorised BDR Pharmaceuticals distributors. Learn more about BDR Pharmaceuticals’ oncology portfolio directly from the manufacturer.
Q. What is Bdparib used for?
Bdparib (Rucaparib) is used as maintenance therapy for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following response to platinum-based chemotherapy, and for the treatment of BRCA1/2-mutated metastatic castration-resistant prostate cancer in patients previously treated with androgen receptor-directed therapy.
Q. What strengths is Bdparib available in?
Bdparib is available in 200mg and 300mg tablet strengths, both manufactured by BDR Pharmaceuticals. Both deliver the same approved 600mg twice daily total dose — the strength selection affects the number of tablets per dose and flexibility for dose reductions.
Q. What is the difference between Bdparib 200mg and Bdparib 300mg?
Both contain the same active ingredient Rucaparib and deliver the same approved 600mg twice daily dose — the 300mg tablets require two tablets per dose while the 200mg tablets require three, providing more flexibility for dose reductions without tablet splitting.
Q. How is Bdparib different from Bracanat or Lynpraza?
All three are PARP inhibitors but contain different active ingredients — Bdparib contains Rucaparib, while Bracanat and Lynpraza contain Olaparib. They have different approved indications and dosing schedules; treatment selection is determined by the treating oncologist.
Q. Is BRCA testing required before starting Bdparib?
For the prostate cancer indication, BRCA1/2 mutation testing is required before treatment. For the ovarian cancer maintenance indication, testing is not required but informs expected benefit, per the approved prescribing information.
Q. Why source Bdparib through A.K. Pharma rather than from a general pharmaceutical wholesale distributor?
As a specialty pharma distribution company focused exclusively on oncology and imported medicines, A.K. Pharma maintains verified sourcing directly from authorised BDR Pharmaceuticals channels — unlike general pharmaceutical wholesale distributors who may source through multiple intermediaries with less traceability. Every Bdparib shipment comes with complete batch documentation.
Q. Is Bdparib available in India?
Bdparib can be supplied to hospitals and oncology centres across India through licensed pharmaceutical distributors. Contact A.K. Pharma — one of Delhi’s most trusted pharmaceutical distribution companies — for availability and pricing.
Q. What is the price of Bdparib in India?
Bdparib price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Bdparib from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Bdparib in bulk?
Yes. As one of Delhi’s established pharmaceutical distribution companies, A.K. Pharma supplies both Bdparib 200mg and 300mg in bulk to hospitals and oncology centres across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
